Search PubMed⌕ Search

Biomedical subjects

M Masuda

Publications and source records attributed to M Masuda.

At least 523 records · Page 29Linked to original sources
PubMed1986

Myocardial protection in coronary occlusion by retrograde cardioplegic perfusion via the coronary sinus in dogs. Preservation of high-energy phosphates and regional function.

The lack of adequate myocardial preservation because of maldistribution of cardioplegic solution in coronary artery disease remains a perplexing problem. We compared two methods of cardioplegic delivery in dogs: antegrade aortic root perfusion (Group I) and retrograde coronary sinus perfusion (Group II). Metabolic changes and regional function in the coronary occlusion model, in which the left anterior descending artery was occluded at its prediagonal portion, were studied. In the distribution of the occluded coronary artery, adenosine triphosphate and total adenine nucleotides at the end of 120 minutes of ischemia were preserved better in Group II (16.80 and 22.94 mumol/gm dry weight) than in Group I (11.06 and 16.19 mumol/gm dry weight, p less than 0.05). Lactate accumulation tended to be higher in Group I than in Group II (114.0 and 87.2 mumol/gm dry weight, respectively; not significant). Percent recovery of segmental shortening was also better in Group II than in Group I (100% and 22.3% at the same left atrial pressure, 4 mm Hg; p less than 0.01). In the region supplied by the intact coronary artery, there were no significant differences between the two groups with regard to metabolic changes and regional function. These observations suggest that retrograde cardioplegic perfusion via the coronary sinus is preferable for surgically treatment of severe coronary artery disease.

Adenine Nucleotides↗
PubMed1986

[Clinical studies on cefixime in pediatrics].

A clinical study of cefixime (CFIX), a new oral cephalosporin, was carried out to evaluate its therapeutic effectiveness on bacterial infections in children. CFIX was orally administered to 13 patients including 6 with upper respiratory tract infection (RTI), 3 with pneumonia, and 1 each with bronchitis, otitis media, skin abscess, and urinary tract infection (UTI). The daily dosage per kg bodyweight ranged from 5.1 to 17.4 mg (average: 8.7 mg), and was given in 2 or 3 divided doses per day for 3 to 10 days (average: 5.8 days). The clinical response was excellent in 4 (30.8%), good in 7 (53.8%) and poor in 2 (15.4%), with an overall efficacy rate of 84.6%. Bacteriological efficacy was good, and 6 of the 8 identified causative organisms were eradicated. Side effects were observed in 3 children, i.e., loose stool in 1 and transient elevations of GOT and GPT in 2. The above results suggest that CFIX is a useful new oral cephalosporin for the treatment of bacterial infections in children.

Bacteria↗
PubMed1985

A new chromogenic endotoxin-specific assay using recombined limulus coagulation enzymes and its clinical applications.

A conventional limulus test is not specific to endotoxin because of the presence in amebocyte lysate of a (1----3)-beta-D-glucan-sensitive factor. By fractionating coagulation enzymes in the lysate and recombining only those factors involved in endotoxin-induced coagulation, we have developed a new test specific to endotoxin. The recombined enzymes reacted only with endotoxin, and not with fungal polysaccharides. Conventional amebocyte lysate, on the other hand, reacted with both of them. A good linearity was obtained with this method between endotoxin concentration and absorbance with a sensitivity of 1 pg/ml of Escherichia coli 0111:B4 endotoxin. The regression lines for different types of endotoxins were parallel to one another. For the correct diagnosis of endotoxemia, this new test has a definite advantage over the one using whole amebocyte lysate.

Arthropod Proteins↗
PubMed1985

Synthesis of proviral DNA in inbred mouse-derived clones of cells expressing different Fv-1 phenotypes.

Formation of proviral DNAs by B-tropic murine leukaemia viruses (MLVs) was examined in N-type and dually permissive mutant cells derived from two inbred mouse strains, DDD and G, both of which are N-type. In the N-type cells, formation of circular proviral DNA was strongly suppressed relative to that of linear DNA. Mutation resulting in loss of the N-type Fv-1 restriction resulted in efficient formation of circular DNA by the previously restricted B-tropic MLV. This showed that Fv-1 restriction and inhibition of closed circular DNA formation were controlled by the same gene. The efficiency of formation of circular proviral DNA by the defective Kirsten murine sarcoma virus was determined by the tropism of the helper virus.

Animals↗
PubMed1985

A comparative immunoperoxidase and histopathologic study of condylomata acuminata.

Thirty-seven lesions from 29 patients with condylomata acuminata were comparatively studied by peroxidase-antiperoxidase (PAP) technique and routine histopathology. PAP staining demonstrated papillomavirus common antigen (PCA) mostly in the granular layer of the epidermis in 22 of 37 lesions (59%) of condylomata acuminata. Presence of PCA is closely correlated with the following histopathologic findings: 1) coarse keratohyalin granules; 2) perinuclear vacuolization or koilocytotic cells in the granular layer; 3) hyperkeratosis with focal parakeratosis. From these findings it is concluded that these histopathologic findings suggest the presence of PCA, and that the presence of papillomavirus may play a role in the formation of these histopathologic features of condylomata acuminata.

Antigens, Neoplasm↗
PubMed1985

Primary malignant lymphoma of the thyroid in a patient with long-standing Graves' disease.

We have recently encountered a patient with rapidly enlarging thyroid masses histologically diagnosed as diffuse histiocytic lymphoma which developed in the active course of Graves' disease. The primary thyroid lymphoma has been in complete remission after local radiation therapy. The association of Hashimoto's thyroiditis and thyroid lymphoma has well been recognized. Meanwhile, data have accumulated to demonstrate that Hashimoto's thyroiditis and Graves' disease share possible similar causal immunological abnormalities and are closely related entities. However, the association of Graves' disease and primary thyroid lymphoma has never been reported, as far as we know. Therefore, this case may be the first one that supports the natural concept that thyroid lymphoma develops from pre-existing Graves' disease secondary to the similar immunological abnormalities in Hashimoto's thyroiditis.

Aged↗
PubMed1985

Dihydromonacolin L and monacolin X, new metabolites which inhibit cholesterol biosynthesis.

Dihydromonacolin L and monacolin X those are structurally related to monacolin K, a potent inhibitor of cholesterol biosynthesis, were isolated from cultures of a mutant of Monascus ruber. The structures of these two metabolites were determined by a combination of physical techniques. Data for dihydromonacolin L and monacolin X as inhibitors of hydroxymethylglutaryl-CoA reductase and sterol biosynthesis in vitro are also given.

Animals↗
PubMed1985

[Clinical studies on aspoxicillin in the field of pediatrics].

Clinical studies were performed as follows on aspoxicillin (ASPC), a new semisynthetic penicillin. ASPC was intravenously given to 12 patients in doses of 57.7-129.0 mg/kg on average) t.i.d. or q.i.d. for 4-7 days (5.7 days on average): 9 with pneumonia, 1 with tonsillitis, 1 with purulent lymphadenitis and 1 with urinary tract infection. The overall efficacy rate was 83.3%, i.e. efficacy was excellent in 8 (66.7%), good in 2 (16.7%), fair in 1 (8.3%) and poor in 1 (8.3%). Bacteriological efficacy was excellent, i.e. 6 of the 6 strains disappeared. No clinical side effects were observed during treatment. Laboratory abnormalities were observed in 3 cases, slight elevation of GOT in 1, slight elevations of GOT and GPT in 1 and mild eosinophilia in 1. The above results suggest that ASPC is an useful antibiotic for treating pediatric bacterial infections.

Amoxicillin↗
PubMed1985

[Clinical experience with ceftizoxime suppositories in bacterial infections in children].

A clinical trial of ceftizoxime suppositories (CZX-S) was performed to evaluate the therapeutic effectiveness in children with bacterial infection. The subjects were 10 children comprising 4 with pneumonia, 3 with lacunar tonsillitis, 2 with pharyngitis, and 1 with UTI. They were given 1 suppository containing either 125 mg or 250 mg of CZX 2 to 4 times a day. The daily per kg body weight dose ranged from 17.1 to 60.0 mg. The result was "markedly effective" in 3, "effective" in 6, and "failure" was recorded in 1. Bacteriologically, successful eradication of causative organisms was confirmed in all the 4 children who underwent the test. No clinical side effects were observed. The only laboratory test abnormality recorded in a single patient was eosinophilia, which was not definitely ascribable to CZX-S. In conclusion, CZX-S have proved to be a clinically safe and effective antibiotic preparation in infantile infection, even in children whose treatment with conventional antibiotics is associated with difficulties.

Bacteria↗